Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial

Gerald Andriole, David Bostwick, Otis Brawley, Leonard Gomella, Michael Marberger, Donald Tindall, Sharon Breed, Matt Somerville, Roger Rittmaster

Research output: Contribution to journalArticle

Abstract

Purpose: Chemoprevention may significantly impact the natural history of prostate cancer. The most potent intraprostatic androgen, dihydrotestosterone, has a significant role in the pathophysiology of prostate cancer. It represents a biologically plausible target for chemoprevention through the inhibition of 5α-reductase isoenzymes. Materials and Methods: The Reduction by Dutasteride of Prostate Cancer Events clinical trial is an international, multicenter, double-blind, placebo controlled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8,000 men will be randomized to receive dutasteride or placebo for 4 years. Eligible men must be 50 to 75 years old, have a serum prostate specific antigen of 2.5 to 10 ng/ml (ages 50 to 60 years) or 3.0 to 10 ng/ml (older than 60 years). Men must have a negative 6 to 12 core biopsy within 6 months prior to enrollment. Repeat biopsies will be taken at 2 and 4 years. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer, and the effect of dutasteride on benign prostatic hyperplasia and prostatitis symptomatology and histopathology will also be assessed. Results: Results remain to be determined. Conclusions: The study will examine the effects of the dual 5α-reductase inhibitor dutasteride on the natural history of prostate cancer in men at increased risk for this malignancy. It affords a unique opportunity to examine biomarkers and genetic linkage for prostate cancer, and assess a range of prostate health outcome measures.

Original languageEnglish (US)
Pages (from-to)1314-1317
Number of pages4
JournalJournal of Urology
Volume172
Issue number4 I
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Chemoprevention
Prostatic Neoplasms
Biopsy
Oxidoreductases
Biomarkers
Placebos
Prostatitis
Genetic Linkage
Dutasteride
Dihydrotestosterone
Prostatic Hyperplasia
Prostate-Specific Antigen
Androgens
Isoenzymes
Prostate
Outcome Assessment (Health Care)
Clinical Trials
Health
Serum

Keywords

  • Prostate prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Chemoprevention of prostate cancer in men at high risk : Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial. / Andriole, Gerald; Bostwick, David; Brawley, Otis; Gomella, Leonard; Marberger, Michael; Tindall, Donald; Breed, Sharon; Somerville, Matt; Rittmaster, Roger.

In: Journal of Urology, Vol. 172, No. 4 I, 01.01.2004, p. 1314-1317.

Research output: Contribution to journalArticle

Andriole, Gerald ; Bostwick, David ; Brawley, Otis ; Gomella, Leonard ; Marberger, Michael ; Tindall, Donald ; Breed, Sharon ; Somerville, Matt ; Rittmaster, Roger. / Chemoprevention of prostate cancer in men at high risk : Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial. In: Journal of Urology. 2004 ; Vol. 172, No. 4 I. pp. 1314-1317.
@article{949e0c0b0fcc40ce88d091f6b411dbdf,
title = "Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial",
abstract = "Purpose: Chemoprevention may significantly impact the natural history of prostate cancer. The most potent intraprostatic androgen, dihydrotestosterone, has a significant role in the pathophysiology of prostate cancer. It represents a biologically plausible target for chemoprevention through the inhibition of 5α-reductase isoenzymes. Materials and Methods: The Reduction by Dutasteride of Prostate Cancer Events clinical trial is an international, multicenter, double-blind, placebo controlled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8,000 men will be randomized to receive dutasteride or placebo for 4 years. Eligible men must be 50 to 75 years old, have a serum prostate specific antigen of 2.5 to 10 ng/ml (ages 50 to 60 years) or 3.0 to 10 ng/ml (older than 60 years). Men must have a negative 6 to 12 core biopsy within 6 months prior to enrollment. Repeat biopsies will be taken at 2 and 4 years. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer, and the effect of dutasteride on benign prostatic hyperplasia and prostatitis symptomatology and histopathology will also be assessed. Results: Results remain to be determined. Conclusions: The study will examine the effects of the dual 5α-reductase inhibitor dutasteride on the natural history of prostate cancer in men at increased risk for this malignancy. It affords a unique opportunity to examine biomarkers and genetic linkage for prostate cancer, and assess a range of prostate health outcome measures.",
keywords = "Prostate prostatic neoplasms",
author = "Gerald Andriole and David Bostwick and Otis Brawley and Leonard Gomella and Michael Marberger and Donald Tindall and Sharon Breed and Matt Somerville and Roger Rittmaster",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/01.ju.0000139320.78673.2a",
language = "English (US)",
volume = "172",
pages = "1314--1317",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 I",

}

TY - JOUR

T1 - Chemoprevention of prostate cancer in men at high risk

T2 - Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial

AU - Andriole, Gerald

AU - Bostwick, David

AU - Brawley, Otis

AU - Gomella, Leonard

AU - Marberger, Michael

AU - Tindall, Donald

AU - Breed, Sharon

AU - Somerville, Matt

AU - Rittmaster, Roger

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Purpose: Chemoprevention may significantly impact the natural history of prostate cancer. The most potent intraprostatic androgen, dihydrotestosterone, has a significant role in the pathophysiology of prostate cancer. It represents a biologically plausible target for chemoprevention through the inhibition of 5α-reductase isoenzymes. Materials and Methods: The Reduction by Dutasteride of Prostate Cancer Events clinical trial is an international, multicenter, double-blind, placebo controlled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8,000 men will be randomized to receive dutasteride or placebo for 4 years. Eligible men must be 50 to 75 years old, have a serum prostate specific antigen of 2.5 to 10 ng/ml (ages 50 to 60 years) or 3.0 to 10 ng/ml (older than 60 years). Men must have a negative 6 to 12 core biopsy within 6 months prior to enrollment. Repeat biopsies will be taken at 2 and 4 years. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer, and the effect of dutasteride on benign prostatic hyperplasia and prostatitis symptomatology and histopathology will also be assessed. Results: Results remain to be determined. Conclusions: The study will examine the effects of the dual 5α-reductase inhibitor dutasteride on the natural history of prostate cancer in men at increased risk for this malignancy. It affords a unique opportunity to examine biomarkers and genetic linkage for prostate cancer, and assess a range of prostate health outcome measures.

AB - Purpose: Chemoprevention may significantly impact the natural history of prostate cancer. The most potent intraprostatic androgen, dihydrotestosterone, has a significant role in the pathophysiology of prostate cancer. It represents a biologically plausible target for chemoprevention through the inhibition of 5α-reductase isoenzymes. Materials and Methods: The Reduction by Dutasteride of Prostate Cancer Events clinical trial is an international, multicenter, double-blind, placebo controlled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8,000 men will be randomized to receive dutasteride or placebo for 4 years. Eligible men must be 50 to 75 years old, have a serum prostate specific antigen of 2.5 to 10 ng/ml (ages 50 to 60 years) or 3.0 to 10 ng/ml (older than 60 years). Men must have a negative 6 to 12 core biopsy within 6 months prior to enrollment. Repeat biopsies will be taken at 2 and 4 years. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer, and the effect of dutasteride on benign prostatic hyperplasia and prostatitis symptomatology and histopathology will also be assessed. Results: Results remain to be determined. Conclusions: The study will examine the effects of the dual 5α-reductase inhibitor dutasteride on the natural history of prostate cancer in men at increased risk for this malignancy. It affords a unique opportunity to examine biomarkers and genetic linkage for prostate cancer, and assess a range of prostate health outcome measures.

KW - Prostate prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=4544248276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544248276&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000139320.78673.2a

DO - 10.1097/01.ju.0000139320.78673.2a

M3 - Article

C2 - 15371831

AN - SCOPUS:4544248276

VL - 172

SP - 1314

EP - 1317

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 I

ER -